首页> 外文期刊>Cancer research: The official organ of the American Association for Cancer Research, Inc >The histone demethylase JMJD2B is regulated by estrogen receptor alpha and hypoxia, and is a key mediator of estrogen induced growth.
【24h】

The histone demethylase JMJD2B is regulated by estrogen receptor alpha and hypoxia, and is a key mediator of estrogen induced growth.

机译:组蛋白脱甲基酶JMJD2B受雌激素受体α和缺氧的调节,是雌激素诱导生长的关键介质。

获取原文
获取原文并翻译 | 示例
           

摘要

Estrogen receptor alpha (ERalpha) plays an important role in breast cancer. Upregulation of HIF-1alpha in ER(alpha)-positive cancers suggests that HIF-1alpha may cooperate with ERalpha to promote breast cancer progression and consequently affect breast cancer treatment. Here, we show the histone demethylase JMJD2B is regulated by both ERalpha and HIF-1alpha, drives breast cancer cell proliferation in normoxia and hypoxia, and epigenetically regulates the expression of cell cycle genes such as CCND1, CCNA1, and WEE1. We also show that JMJD2B and the hypoxia marker CA9 together stratify a subclass of breast cancer patients and predict a worse outcome of these breast cancers. Our findings provide a biological rationale to support the therapeutic targeting of histone demethylases in breast cancer patients.
机译:雌激素受体α(ERalpha)在乳腺癌中起重要作用。 HIF-1alpha在ERα阳性癌症中的上调表明HIF-1alpha可能与ERalpha协同促进乳腺癌的进展并因此影响乳腺癌的治疗。在这里,我们显示了组蛋白脱甲基酶JMJD2B受ERalpha和HIF-1alpha的调节,在常氧和低氧状态下驱动乳腺癌细胞增殖,并在表观遗传上调节细胞周期基因(例如CCND1,CCNA1和WEE1)的表达。我们还显示,JMJD2B和缺氧标记物CA9共同对乳腺癌患者的一个亚类进行分层,并预测这些乳腺癌的预后较差。我们的发现提供了生物学原理来支持乳腺癌患者中组蛋白脱甲基酶的治疗靶向。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号